Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
rare diseases
Biotech
Relay ‘full steam ahead’ on PI3K drug after rare disease readout
Relay’s R&D chief remains convinced zovegalisib will carve out its own niche after reporting early phase 2 data in patients with vascular anomalies.
Will Maddox
May 19, 2026 6:00am
Sanofi, Wave post updates in race to end AATD’s 40-year drought
May 18, 2026 4:30pm
BioMarin’s $270M Inozyme rare disease bet misses key ph. 3 goal
May 18, 2026 11:05am
Cash-strapped Quince finds salvation in reverse merger
May 18, 2026 10:32am
Aardvark to dig into phase 3 data early after FDA imposes hold
May 15, 2026 1:51am
Kyverna begins rolling FDA submission for autoimmune CAR-T in SPS
May 12, 2026 4:27pm
